NEW YORK (GenomeWeb) – South Korean genomic services provider Macrogen announced today that it has acquired a non-exclusive research tool license to CRISPR-Cas9 technology from the Broad Institute.

Macrogen said that it intends to use the genome-editing technology to build preclinical animal models and for target treatment function analysis to advance precision medicine and gene therapy research and development.

Specific terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.